More than three months ago, investors first learned that ivonescimab, a PD-1/VEGF-targeting bispecific antibody from Summit Therapeutics and Akeso Pharmaceuticals Inc., bested Keytruda (pembrolizumab) ...

Affirm Holdings is nearing GAAP operating profitability, driven by strong gross merchandise volume growth and improving customer monetization. The expanding BNPL and e-commerce markets provide a ...